SARS-CoV-2 Assessment of Viral Evolution Collaborating Institutions

Federal Agencies and Laboratories

  • Centers for Disease Control and Prevention (CDC)
  • Food and Drug Administration, Center for Biologics Evaluation and Research (FDA)
  • Biomedical Advanced Research and Development Authority (BARDA)
  • Los Alamos National Laboratory (LANL)
  • NIAID, National Institutes of Health, Division of Microbiology, and Infectious Diseases (NIAID, DMID)
  • NIAID, National Institutes of Health, Integrated Research Facility-Frederick  (NIAID, IRF)
  • NIAID, National Institutes of Health, Vaccine Research Ce

Tratamiento ambulatorio con inmunoglobulina anticoronavirus (Outpatient Treatment with Anti-Coronavirus Immunoglobulin, OTAC)

Un estudio de investigación que prueba un tratamiento contra el COVID-19 en fase de investigación conocido como concentrado de inmunoglobulinas de administración intravenosa hiperinmunitarias (hIVIG) anticoronaviral.

Outpatient Treatment With Anti-Coronavirus Immunoglobulin (OTAC)

A research study testing an experimental COVID-19 treatment called anti-coronavirus hyperimmune intravenous immunoglobulin (hIVIG).

Scientific Advances at the Vaccine Research Center

Notice of Special Interest (NOSI) Pediatric COVID-19 and Respiratory Viral Co-infection

SARS-CoV-2 Assessment of Viral Evolution Publications

Seattle Children’s Researchers Discover that Nanobodies Could Pack the Biggest Punch Against COVID-19 Variants and Resurgence

Link Type
Funded-research
Media Type
Article
Publish or Event Date
Link URL
https://pulse.seattlechildrens.org/seattle-childrens-researchers-discover-that-nanobodies-could-pack-the-biggest-punch-against-covid-19-variants-and-resurgence/
Research Institution
Seattle Children’s Research Institute
Short Title
Seattle Children’s Researchers Discover that Nanobodies Could Pack the Biggest Punch Against COVID-19 Variants and Resurgence
Content Coordinator
Claudia Wair
Content Manager
Kathy Donbeck

SKI Research Reveals New Insights into Immune Response to Viral Infections — Including COVID-19

Link Type
Funded-research
Media Type
Article
Publish or Event Date
Link URL
https://www.mskcc.org/news/sloan-kettering-institute-research-reveals-new-insights-immune-response-viral-infections-including-covid-19
Research Institution
Sloan Kettering Institute
Short Title
SKI Research Reveals New Insights into Immune Response to Viral Infections
Content Coordinator
Claudia Wair
Content Manager
Kathy Donbeck

Cross-cutting Pandemic Preparedness Efforts

The ability of NIAID to prepare for and mount a rapid and effective research response to an emerging pathogen relies on knowledgeable staff, up-to-date facilities and flexible infrastructure, cutting-edge technology, and a robust, centralized coordination hub.

Pandemic Preparedness Translational and Clinical Research

Diagnostics

NIAID will leverage its expertise in infectious diseases, genomics, proteomics, bioinformatics, and access to clinical samples to develop rapid-response diagnostics for biological threats and emerging infectious diseases. In close collaboration with other NIH institutes and USG agencies, NIAID will support the development new and improved point-of-care and home-based tests as well as ultrahigh-throughput central reference laboratory testing that can accurately detect signatures of infectious pathogens that are of high public-health consequence.

Subscribe to